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ABSTRACT. The immunogenicity of individual diethylnitrosamine (DEN)-induced forestomach carcinomas in
female BALB/c mice was investigated following in vitro and in vivo cultivation. Of the five transplantable
tumor lines studied, (DEN1? DEN3, DEN6, DEN8, and DEN^ only two (DEN6 and DEN8) showed some degree of
immunogenicity. DENX, E»EN3, and DEN9 were highly tumorigenic with very little immunogenic potency as
judged by tumor transplantation-excision assay, Winn neutralization, and antibody binding tests. These
three tumors grew rapidly and showed a high degree of malignancy. DENX and DEN3 also metastasized readily.
Cell lines from DEN6 and DEN9 lost their tumorigenicity at the 5th and 50th passage of culture, respectively.
Although DENa and DEN3 did not lose their tumorigenicity, the number of tumor cells required to produce
tumors increased substantially and their ability to metastasize was lost. Tumor transplantation studies, with
these cultured cell lines in normal and x-irradiated recipients, suggested that the decrease in tumorigenicity
may be immunologically mediated. Mice immunized with the in vitro lines demonstrated transplantation
resistance against the respective in vitro and in vivo lines. The treatment of in vivo or in vitro propagated
cells with periodic acid or neuraminidase enhanced antigen-antibody binding significantly. The effect of
these chemicals became less pronounced as in vitro culture continued. It appears that during in vivo
cultivation the antigenic determinants are masked or modulated by some glycoprotein or glycolipid
molecules which render them non-, or very weakly, immunogenic.
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INTRODUCTION
Multiple factors appear to be involved in the control
and development of oncogenic diseases. Among these
factors, elements of immune response undoubtedly play
an important role in some tumor systems. However, for
the immune mechanisms to be effective in controlling
oncogenic diseases, tumors must express appropriate
tumor-associated antigen(s). The presence of tumor-
associated antigen(s) is common on cell surfaces of
tumors induced by chemical carcinogens or oncogenic
viruses (North 1984, Schreiber et al. 1988). Such antigen(s),
however, has not been demonstrated as a common fea-
ture of many spontaneously arising tumors (Hewitt et. al.
1976, Klein and Klein 1977). For this reason, many
attempts have been made using different chemicals
(Bonmassar et al. 1970, Contessa et. al. 1981, Frost et. al.
1984, Ishikawa et. al. 1987), viruses (Kobayashi et. al.
1969, Boon 1983, Altevogt 1986, Fearon et. al. 1988),
mutagens (Boon 1983), and factors such as cholesterol
derivatives (Ludes et al. 1990) and interleukin 6 (Mullen
et al. 1992), to enhance immunogenicity and to reduce
tumorigenicity of some malignant tumor cells.
In some of the previous investigations, we reported
that with increased in vitro passage, the immunogenicity
of several respiratory squamous cell carcinomas (that is,
the ability of tumor cells to induce cellular and humoral
immunity in syngeneic hosts) was increased while their
tumorigenicity decreased (Jamasbi and Nettesheim 1977,
'Manuscript received 17 December 1992 and in revised form 14
October 1993 (#92-32).
Correspondence and reprint requests should be addressed to: Dr. R.
J. Jamasbi, Department of Medical Technology, Bowling Green State
University, Bowling Green, OH 43403, U.S.A.
1979). Similar observations have also been reported by
other investigators using different tumor models (Ossow-
ski and Reich 1980, Correll et. al. 1983, Yamashina et. al.
1986, Chiba et. al. 1987). Although some speculations
concerning the mechanism(s) of increased immunogen-
icity of cultured cell lines have been made, the exact
nature of this phenomenon remains unknown.
The main objectives of the present investigation were
to study the biological and immunological characteristics
of five different mouse forestomach carcinoma lines and
to determine whether the tumorigenicity and immuno-
genicity of some of the highly malignant tumor lines could
be altered by in vitro cultivation. If so, efforts would be
made to determine whether the underlying mechanism(s)
can be elucidated.
MATERIALS AND METHODS
Animals
Syngeneic BALB/c female mice, 8-12 weeks of age
were used throughout these experiments. They were bred
and maintained in a conventional animal facility and had
free access to food and water.
Tumors
Five forestomach carcinoma lines were used. These
tumors developed in the forestomach of female BALB/c
mice which had received DEN in their drinking water
for eleven weeks (40 fig/1, cumulative dose 350 |ig/kg
of body weight) as reported previously Qamasbi and
Perkins 1990). These tumors were designated DENi;
DEN3, DEN6, DEN8, and DENy. Histologic examination of
transplanted tumors showed that all of the tumors were
invasive squamous cell carcinomas. The syngeneic sar-
coma cell line, designated MSC (Kennel et al. 1985), was
used as a control.
OHIO JOURNAL OF SCIENCE R. J. JAMASBI 15
In all experiments tumor cells were inoculated
intramuscularly (i.m.) in the thigh of syngeneic mice. The
transplantability of each tumor line was determined by
serial passage in vivo. At the fifth in vivo passage, tumors
were removed, single cell suspensions were prepared by
trypsinization, and a large cell pool was established and
stored in liquid nitrogen. Cells from the fifth in vivo
passage were used for the majority of in vivo experiments
and for the establishment of tissue culture cell lines.
The relative tumorigenicity of each carcinoma line was
determined by injecting graded doses of tumor cells.
Tumor development, growth, rates, and time and incidence
of mortality were determined.
Metastatic characteristics of these tumors were studied
as described previously (Jamasbi and Perkins 1990).
Briefly, mice were inoculated with 105 tumor cells and
the tumor was removed when it reached 1-1.5 cm in
diameter. Thirty days later the animals were killed and
examined for the incidence of metastasis.
In Vitro Culture
Culture media, sera, and antibiotics were obtained
from Grand Island Biological Co. (Grand Island, NY).
Tissue culture procedures and the establishment of epi-
thelial cell lines from these tumors were as previously
described (Jamasbi and Perkins 1990). Briefly, cell lines
were derived from the fifth in vivo tumor passage by
explant culture of tumor fragments in McCoy's medium
supplemented with 10% fetal bovine serum (FBS). All
cultures were incubated at 37° C in a humidified atmos-
phere of 5% CO2 in air. When sufficient epithelial out-
growth was observed, cells were subcultured. All of the
cell lines were screened periodically for mycoplasma
contamination (Hayflick 1965). Tissue culture cell lines
were developed from all tumors except DENg.
In Vitro Growth Properties
For determination of seeding efficiency, growth rate,
and cell doubling times, cell lines were plated at a density
of 105 cells per 100 mm plastic dish. Cells from two dishes
were independently harvested by trypsinization each
day and counted using a hemacytometer. Results were
plotted on semilogarithmic paper, and doubling times
calculated.
Transplantation Tests
To test the tumorigenicity of in vivo or in vitro pas-
saged tumor cells, different doses of cells were inoculated
into syngeneic hosts. Cultured cells were tested for their
tumorigenicity after every fifth passage for 25-50 pas-
sages. In vivo propagated cells were serially transplanted
into syngeneic hosts for an additional five times. Thighs of
inoculated mice were checked at weekly intervals for
tumor development. Rates of tumor growth and inci-
dence of mortality were recorded.
Fluorescent Antibody Assay
In order to analyze cells for viral antigens, tumor cells
were grown on coverslips. When the cells reached near
confluency, the coverslips were washed in PBS and
adherent cells were fixed in cold acetone. The cells were
then incubated with broadly reactive antibodies from a
rat immunized against mouse Moloney leukemia and
Moloney sarcoma viruses. The cells were washed in PBS,
incubated with goat anti-rat serum (fluorescein conju-
gated), and counter-stained with rhodamine. Positive cells
were observed using an ultraviolet microscope.
Immunization and Challenge (In Vivo Tumor
Lines)
To determine tumor immunogenicity, previously
described immunization procedures were used (Jamasbi
et al. 1978). For this purpose, mice were injected i.m. with
1O3-1O5 live tumor cells. Tumors were removed 3-4 weeks
later when tumor size reached 1-1.5 cm in diameter. One
week later the animals were challenged with graded
doses of in vivo parental tumor cell lines. Because of the
apparent absence of immunogenicity of some of these
tumor lines, transplantation-excision procedures were
repeated 2-3 times to determine whether immune respon-
ses (resistance) could be generated. Immunization by
x-irradiated cells (Jamasbi and Nettesheim 1979) was
also attempted. Mice immunized with MSC or receiving
sham surgery served as controls.
Immunization and Challenge (In Vitro Tumor
Lines)
For immunization with in vitro grown cell lines, 106
cells in 0.1 ml PBS from different in vitro passages were
inoculated into syngeneic recipients. Tumors which
developed in some of the hosts were surgically removed
when they grew to about 1-1.5 cm in diameter (3-5 weeks
later), and the animals were challenged with appropriate
in vivo or in vitro cell lines 7-10 days later. In all of the
preceding experiments normal mice which had under-
gone sham surgery or mice immunized with MSC served
as controls.
Winn Neutralization Test
To determine the cytotoxic effect of the immune
spleen cells on the tumor development, the Winn
neutralization test was conducted. For this purpose,
spleens from either normal or immunized mice were
aseptically removed and pooled (3-5 spleens/group).
Single-cell suspensions were prepared and mixed at a
ratio of 200:1 with tumor cells using the smallest tumor
cell dose that produced 100% tumor takes for each
respective tumor line. The mixture was incubated at 37°
C for 1 hr, and inoculated i.m. into the thighs of normal or
x-irradiated mice (450r x-rays). Control groups received
tumor cells only or tumor cells mixed with spleen cells
from either normal mice or mice which had been immun-
ized with MSC tumor cells.
Antibody-binding Test
To demonstrate an antibody in the sera of mice
immunized against each tumor, an enzyme-linked
immunosorbent assay (ELISA) was used. To perform
ELISA, in vitro propagated cells were cultured into 96-well
plates (Corning) and fixed with 0.1% glutaraldehyde
(Sigma) for 10 min at room temperature. The fixed cells
were treated with 0.1 M glycine for 5 min and were then
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exposed to 1% bovine serum albumin in phosphate-
buffered saline, pH 7.2 (BSA-PBS) for 1 h. Properly di-
luted (1:500) immune or non-immune sera were added
at 100 |il/well and allowed to react for 1 h at 37° C. The
plates were washed three times with PBS and incubated
at 37° C for 1 h with 100 |il/well of a 1:250 dilution (in
2% BSA-PBS) of 13-galactosidase-conjugated goat anti-
mouse immunoglobulin (Southern Biotechnology
Associates, Inc.). After the incubation, the plates were
washed three times with PBS and incubated with 100 fil/
well of p-nitrophenyl-fi-D-galactopyranoside (Sigma)
solution (1 mg/ml in phosphate buffer, pH 8.5) at 37° C
for 1 h. The optical density (at 410 nm) was measured
with an MR-600 microwell plate reader (Dynatech
Laboratories, Inc.). In some ELISA experiments, when in
vivo propagated cells were to be tested, a 105 cells/well
of either in vivo or in vitro (for comparison) were attached
to poly-L-lysine treated wells, fixed and examined as
above. Cultured MSC cells served as controls.
Periodic Acid Treatment
To determine whether the binding of immune sera to
the tumor cells can be altered by periodic acid treatment,
glutaraldehyde-fixed cells in 96-well plates were treated
with 100 mM periodic acid solution (Sigma) at 37° C for 30
min. The wells were washed with PBS three times and the
reactivity of the antibody with the treated and untreated
cells was determined by ELISA.
Enzyme Treatment
The effect of neuraminidase (Sigma) treatment on the
binding of immune sera to in vivo and in vitro propagated
cells was also assessed. Glutaraldehyde-fixed cells in 96-
well plates were exposed to a 0.5 mU/well of neuraminidase
(in 50 mM sodium acetate buffer, pH 5.5), for 1 h at 37° C.
Control wells were exposed to 100 uj of sodium acetate
buffer. Following enzyme treatment, the wells were
washed 3 times with PBS; then antigen-antibody binding
was assessed by ELISA.
RESULTS
Growth Characteristics of In Vivo Propagated
Tumor Lines
The degree of tumorigenicity varied considerably among
the forestomach carcinomas of BALB/c mice (Table 1).
Whereas the 103 viable cells of DEN:, DEN3, or DEN9
produced tumors in 100% of the inoculated hosts, a much
higher (approximately 100-fold) tumor cell dose (105) of
DEN6 or DENg was needed to obtain similar results. This
experiment was repeated several times using a different
range of tumor cell concentrations. Only those which
gave approximately 10-100% tumor takes are presented
(Table 1). Growth rates of in vivo propagated DEN17 DEN3,
and DEN tumor lines (data not shown) were also much
greater than those observed for DEN6 and DENg.
The rate of mortality (Table 2) also differed consid-
erably among mice that received cells from different tumor
lines, i.e., 105 cells of DENj killed all mice between 6-8
weeks whereas the same dose of DEN3, DEN6, DENg, or
DEN? tumor cells killed the injected mice between 9-11,
20-24, 18-23, and 7-11 weeks, respectively. Highly
malignant, fast-growing DENX and DEN metastasized
readily (Table 2). DENX metastasized faster and produced
micrometastases and secondary tumors in many organs,
including the lungs, kidneys, and renal lymph nodes,
while DEN3 primarily metastasized to the lungs and
occasionally to the renal lymph nodes. Surprisingly,
aggressively growing, highly malignant DENg did not
metastasize. Relatively slow growing DEN6 and DENg did
not metastasize, either.
Growth Characteristics of In Vitro Propagated
Tumor Cell Lines
Epithelial outgrowths from the tumor explants in the
culture grew slowly and subcultures were generally not
possible until 5-6 weeks after the primary culture
(Jamasbi and Perkins 1990). Once fibroblast-free epithelial
cultures were established, the cells grew more rapidly and
subcultures were routinely made at weekly intervals.
TABLE 1
Demonstration of tumorigenic potency of in vivo propagated carcinoma lines?
Time after
tumor cell
injection
(weeks)
2
4
6
8
10
12
103
2/5
5/5
5/5
5/5
5/5
5/5
D E Ni
5X102
0/5
0/5
2/5
3/5
4/5
4/5
102
0/5
0/5
0/5
2/5
2/5
2/5
103
0/5
3/5
4/5
5/5
5/5
5/5
DEN3
5X102
0/5
0/5
1/5
3/5
3/5
3/5
102
0/5
0/5
0/5
0/5
0/5
1/5
105
0/5
2/5
5/5
5/5
5/5
5/5
DEN6
5X104
0/5
1/5
2/5
3/5
3/5
3/5
104
0/5
0/5
1/5
1/5
1/5
1/5
105
0/5
5/5
5/5
5/5
5/5
5/5
DEN
104
0/5
4/5
4/5
4/5
4/5
4/5
8
5X103
0/5
1/5
1/5
1/5
1/5
1/5
103
0/5
3/5
5/5
5/5
5/5
5/5
DEN9
5X102
0/5
0/5
2/5
2/5
2/5
2/5
102
0/5
0/5
0/5
1/5
1/5
1/5
aGraded doses of single cell suspensions of each tumor line (fifth in vivo passage) were injected i.m. into the thighs of five syngeneic mice. Only the
tumor cell doses that gave -10-100% tumor takes are reported here. Number of mice with tumors/number of mice injected.
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TABLE 2
Time to mortality of mice receiving 105 cells from different
carcinoma lines1 and the incidence of metastasis.
Tumor Line
DENa
DEN3
DEN6
DEN8
DEN9
Time to mortality
(weeks)b
6-8
9-11
20-24
18-23
7-11
Incidence of
metastasis0
100%
80%
0
0
0
aSingle cell suspensions (fifth in vivo passage) of each cell line were
injected i.m. into thighs of 10 syngeneic mice and incidence of
mortality was recorded.
bFirst number indicates the week when the first mouse died and the
second number when the last mouse died.
'Mice were injected i.m. (thigh) with 10^ tumor cells. The tumors were
removed when they reached 1-1.5 cm. Animals were killed 30 days
later and organs examined for the presence of metastasis.
Each cell line exhibited its own distinct morphological
characteristics (Fig. 1) and, when injected into syngeneic
hosts at early passage in vitro CP10); these cell lines pro-
duced squamous cell carcinomas similar to those produced
by the parental tumor line propagated in vivo (Fig. 2).
The in vitro growth characteristics of the various cell
lines were determined at the 10th-15th passage. Seeding
efficiency (as determined by the number of cells attached
at 24 hr) was 63, 54, and 71% for DEN1? DEN3, and DEN?,
respectively. The population doubling times for these
tumors were 14, 20, and 16 h, respectively.
At every fifth in vitro passage, graded cell doses of each
carcinoma line were inoculated into syngeneic recipients
to determine if the tumor line retained its tumorigenicity.
Results (Table 3) show that the highly malignant,
metastasizing DENX and DEN3 cell lines retained a relatively
high degree of tumorigenicity up to the 50th in vitro
passage (more recent examination of these cell lines
showed that they retained tumorigenicity to the 100th
passage or greater). However, both lines showed
considerable reduction in their tumorigenicity as judged
by the increasing number of cells required to induce a
tumor take at late passages. DEN also highly malignant
but non-metastasizing, lost its tumorigenicity at about the
50th in vitro passage.
Although DEN6, was not tumorigenic at the highest
dose tested (105) at the fifth in vitro passage, tumors
readily developed in x-irradiated hosts (100%). The
tumorigenicity of the other cell lines was also enhanced
when inoculated into x-irradiated mice (data not shown).
Thus, the results reveal diverse biological characteristics of
these tumor lines.
Determination of Transplantation Immunity of
the In Vivo Line
Transplantation-excision-challenge experiments were
conducted to determine immunogenic potency of the in
vivo tumor lines. "Immunized" mice were challenged
with graded doses of tumor cells. Untreated, sham-
operated mice and mice immunized with MSC cells were
also tested. For the sake of brevity, results of these
experiments were not tabulated. Briefly, no transplanta-
tion resistance was demonstrated in mice immunized
(receiving 2-3 transplantation excisions) against DENj or
DEN3. Mice immunized with DEN9 showed marginal
resistance to a subsequent challenge (7 of 10 mice
developed tumors). However, the slow growing, non-
metastasizing DEN6 and DENg tumor cell lines showed a
significant degree of protection (2 of 10 mice developed
tumors). Other methods of immunization (e.g., use of
irradiated cells) failed to confer protection against any of
these tumors. Control mice, immunized against MSC or
receiving sham surgery, showed no protection against
these tumors.
DENj, DEN3, and DEN9 were found negative for cell-
associated viral antigens by the indirect fluorescent anti-
body test using antibody to mouse-leukemia and sarcoma
viruses 0amasbi and Perkins 1990). DEN8 was not tested
and DEN, was positive. Whether the higher degree of
TABLE 3
Demonstration of tumorigenic potency of tumor cell lines at different in vitro passages':
Tumor
cell
line
DENX
DEN3
DEN6
DEN9
105
100
100
0
100
P5
104
100
100
0
100
5X103
100
100
0
100
105
100
100
0
100
pw
104
100
100
0
100
5X103
100
ND
0
100
105
100
100
0
100
104
100
80
0
80
5X103
100
40
0
40
105
100
80
ND
60
P30
104
80
50
ND
20
5X103
60
20
ND
0
105
100
60
ND
20
P40
104
80
30
ND
0
5X1O3
40
10
ND
0
105
80
60
ND
0
104
60
20
ND
0
5X1O3
20
10
ND
0
aGraded doses of single cell-suspensions were injected into the thighs of 10 syngeneic mice. Tumor takes (percentage) were recorded for 24 weeks.
DENg were tumorigenic at passage 3 in vitro. DENg (P10) and DEN9 (P50) produced tumors in x-irradiated (450 r) mice.
ND = not done.
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FIGURE 1. Cytological appearance of epithelial cell lines derived from different forestomach carcinomas propagated in vitro for 15 passages
(Phase Contrast X 250). A, DEN • B, DEN • C, DEN • D, DENO.
r 3 6' ' 9
immunogenicity of DEN6 tumor cell line was related to
viral antigen has yet to be determined.
The cytotoxic effect of spleen cells from "immunized"
mice (receiving 3 transplantation excisions) on the develop-
ment of the homologous tumor was examined by the Winn
neutralization test. Spleen cells from mice immunized
against DEN6 or DENg caused 60% and 50% inhibition,
respectively. This type of inhibition was not observed
with the other tumors, indicating that only DEN6 and DENg
could induce detectable immunity. Normal spleen cells or
spleen cells from mice immunized with the MSC line had
no inhibitory effect on the incidence of tumor develop-
ment (data not shown). The results were very similar
whether normal or x-irradiated recipients were used.
For the detection of binding antibody in the sera of
mice immunized against their respective in vivo or in
vitro tumor cells, indirect ELISA was used. No detectable
binding could be demonstrated in the sera of mice
immunized against the in vivo propagated DENi; DEN3 or
DEN9 (Table 4), indicating that the in vivo tumor lines
are incapable of inducing detectable binding antibody.
Sera of mice immunized against DEN6 (in vivo) showed
some reactivity against the respective tumor celis and sera
of mice immunized with in vitro propagated tumor cells
demonstrated significant binding capacity (Table 4). The
binding of immune sera to control cells (MCS) was in-
significant (data not shown).
Determination of Transplantation Immunity of the
In Vitro Line
To determine the immunogenic potency of the cell
lines grown in vitro and to compare these results with
those obtained using their in vivo counterpart, cultured
cells of the highly malignant DENa, DEN3, and DEN9 tumor
cell lines were selected for detailed investigation. Syn-
geneic mice were injected with the cultured cells (P3Q);
and, if tumors developed, they were excised and the
procedure was repeated one or two times. These mice
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FIGURE 2. Histological appearance of different forestomach carcinoma produced by injection of tumor cell lines grown in vitro (X 250). DEN,
(A), after 10 serial in vivo passages; (B), after 10 serial in vitro passages and 1 in vivo passage; DEN3 (C), after 10 serial in vivo passages;
(D), after 10 serial in vitro passages and 1 in vivo passage; DEN9 (E), after 10 serial in vivo passages; (F), after 10 serial in vitro passages and
1 in vivo passage.
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TABLE 4
Detection of binding antibody in the sera of mice "immunized"
against in vivo or in vitro propagated tumor cells by ELISA?
Cell
Line
DENj
DEN3
DEN6
DENc;
Absorbance at 410 nm(b)
Sera from mice
immunized with
in vivo cells
0.15 ±0.02
0.20 ± 0.03
0.85 ±0.10
0.20 ± 0.05
Sera from mice
immunized with
in vitro cells
1.00 ± 0.05
1.30 ±0.10
1.70 ±0.20
1.50 ±0.10
Sera from
normal
mice
0.12 ±0.03
0.10 ±0.02
0.20 ± 0.06
0.10 ±0.04
aSera of mice "immunized" with in vivo and in vitro propagated tumor
cells (1:500 dilution) were tested against each respective cultured
tumor cells by ELISA. No significant bindings were detected with MSC
cells (data not shown).
l5The values are the means of triplicate samples ± S.D.
were then challenged with in vivo (passage 5) or in vitro
(passage 30) parental cell lines. Results of these experi-
ments (Table 5) showed that with this procedure, not only
could we demonstrate a significant degree of protection
against challenge with the in vitro line, but also against
the fast-growing-metastasizing in vivo parental cell line.
Such protection suggested enhanced immunogenicity
of these tumor lines during in vitro cultivation.
TABLE 5
Effect of immunization with in vitro propagated DENh
DEN^, or DENc,. Cells on the transplantability of their
respective in vitro and in vivo tumor cells?-
Challenge dose
In vitro grown
tumor cells used
for challenge
DENj
DEN,
DEN9
In vivo grown
tumor cells used
for challenge
DENj
DEN3
DEN9
105
105
105
103
103
104
Recipients
Immunized Sham operated
3/10
2/10
0/10
6/10
5/10
4/10
10/10
10/10
10/10
10/10
10/10
10/10
aMice were immunized with DEN1; DEN3, or DEN9 in vitrolines (3x) and
were then challenged with their corresponding in vitro and in vivo
propagated lines. Number of mice with tumors/number of mice
challenged. Mice immunized with the control syngeneic sarcoma line
(MSC) showed no protection against the challenges (data not shown).
Effect of Periodic Acid and Neuraminidase
Treatment on Antigen-antibody Binding
It is well known that periodic acid can cleave
carbohydrate moieties from glycoprotein or glycolipid
molecules (Ravindranath et. al. 1989, Naito et. al. 1990)
and neuraminidase can cause sialic acid release (Bekesi
et. al. 1972, Ogasawara et al. 1988). To determine whether
the exposure of in vivo or in vitro propagated tumor cells
to the above chemicals influences the antigen-antibody
binding test, experiments were conducted in which the
cells were exposed to periodic acid or neuraminidase.
The antigen-antibody binding was determined by ELISA.
The results (Table 6) showed that exposure of the cells to
these chemicals enhanced antigen-antibody binding
significantly. It should be noted that periodic acid had
a greater effect than the neuraminidase treatment. It
appears that during the in vivo or early in vitro cultivation,
the antigenic determinants of these tumor cells are masked
by some glycoprotein or glycolipid molecules that inter-
fere with antigen-antibody binding and render them very
weak or non-antigenic. The removal of the carbohydrate
side chains or sialic acid residue from the interfering
glycolipids and/or glycoproteins appears to increase
epitope accessibility, thus enhancing their binding capacity
to the antibody.
When the effect of periodic acid on the antigen-
antibody binding was studied using different in vitro
passages (Table 7), it was found that the influence of these
chemicals on the antigen-antibody binding decreased as
the passage in culture continued. It appears that during in
vitro cultivation, concentrations of masking or interfer-
ing molecules gradually decreased, the antigenic
determinants become exposed, and consequently the
tumor cells demonstrated greater antibody binding
capability. However, concentrations of the masking or
interfering substances appeared to be different on different
tumor cells, since some of the cell lines lost their
tumorigenicity at an early in vitro passage, while others
retained their tumorigenicity for a much longer period of
time. It is also possible that quality and/or quantity of the
antigenic determinants are not the same on the different
cell lines.
DISCUSSION
Existing evidence suggests that most chemically-induced
tumors possess unique tumor-associated antigens capable
of generating immune responses in syngeneic hosts
(Baldwin 1974, Schreiber et al. 1988). In contrast, in our in
vivo experiments, three (DENi; DEN3, and DEN9) of the
five DEN-induced tumor lines used were fast growing,
highly malignant, and showed very little immunogenicity
despite repeated attempts using different methods of
immunization and/or protocols (e.g., use of irradiated
tumor cells, repeated transplantation-excision procedures).
None, or only marginal, protection was demonstrated
even against the smallest tumor cell challenge (103).
Furthermore, demonstrable cellular or humoral immunity
could not be detected using the Winn neutralization test
or the antibody-binding assay.
As we increased the number of in vitro passages, a
marked decrease in tumorigenicity with a loss of metastatic
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TABLE 6
Effect of periodic acid and neuraminidase treatment on the
antigen-antibody binding by ELISA :x
Tumor cells
propagated
in vitro (P=)
DENj
DEN,
DEN9
Tumor cells
propagated
in vivo (/^)
DEN:
DEN,
DENc;
% Increase in antigen-antibody binding'5
Periodic Acid
109.5 + 5.0
114.3 ± 6.2
140.6 ± 5.6
81.50 ± 5.5
93.20 ± 6.0
105.6 ± 8.5
Neuraminidase
42.60 ± 1.9
38.00 ± 1.4
20.60 ± 1.3
ND
ND
ND
aTumor cells (KP/well) were fixed into poly-L-lysine treated, microtiter
plates, fixed with 0.1% glutaraldehyde and treated with 100 mM
periodic acid in PBS (100 (il/well) and 0.5 mU/well of neuraminidase
(in 50 mM sodium acetate buffer, pH 5-5) at 37° C for 30 minutes. The
untreated cells, incubated with appropriate buffers, served as controls.
The binding of antibody (1:500 dilution of sera of mice immunized with
different cell lines) to the treated and untreated cells was measured by
ELISA.
% increase in the binding of antibody was calculated by the
following formula:
% increase = P .P . (untreated) - P .P. (treated) x 100
O.P. (untreated)
lyThe values are the means of triplicate samples ± S.D.
ND = not done.
Normal mouse serum did not show any significant binding to the treated
or untreated cells (data not shown).
capability was observed. This occurred concomitantly
with an increase in immunogenicity, as judged by the
increasing number of cells that were required to produce
tumors, as passage in culture continued, and by the
presence of binding-antibody in the immune sera. Loss of
metastatic capability as a result of in vitro cultivation has
been observed in other tumor systems, indicating that this
phenomenon is not uncommon (Ossowski and Reich
1980, Belardelli et. al. 1984). The increasing experimental
evidence indicates that the integrin family of adhesion
molecules plays a major role in tumor invasion and
metastasis (Natali et al. 1993, Dedhar 1990). Whether the
loss of metastatic potential observed in the present study
is caused by alteration in the expression of adhesion
molecules is not clear and requires further study.
It has been shown that concentrations of FBS in growth
media can influence the immunogenicity of tumor cell
lines (Chiba et. al. 1987). This was not the case in our
experiments since the tumor cells cultured in medium
containing 0.5% or 10% FBS showed no significant
differences in antigen-antibody binding. In addition, the
growth of tumor cells in media containing syngeneic
mouse sera did not influence the results (data not shown),
indicating that not all tumor systems react similarly to the
environment of in vitro cultivation.
The demonstrated increase in immunogenicity appears
to be significant. This became evident with our protection
studies wherein animals that were immunized with
the in vitro line were protected not only against the
immunizing in vitro line but also, at least to some degree,
against the highly malignant, metastasizing parental in
vivoline. In contrast, immunization with these in vivo
lines repeatedly failed to confer any significant degree of
protection. Furthermore, the tumorigenic potency of in
vitro lines was enhanced and/or recovered when the
cells were inoculated into x-irradiated (immuno-
suppressed) mice. Similar phenomena have been observed
by other investigators (Correll et. al. 1983, Altevogt 1986).
Thus, the present data, as well as observations made by
other investigators (Mullen et al. 1992), indicate that
concomitant with the development of decreased
tumorigenicity, tumor cells become more immunogenic
and less metastasizing.
It has been shown that periodic acid can cleave
carbohydrate moieties from glycolipid or glycoprotein
molecules (Ravindranath et. al. 1989, Naito et. al. 1990).
In the present study, it was found that exposure of the
tumor cells to this oxidizing agent enhances antigen-
antibody binding considerably, suggesting that some
glycolipid and/or glycoprotein molecules on surfaces of
the cells interfere with antigen-antibody bindings. The
TABLE 7
Effect of periodic acid treatment on antigen-antibody binding test
using different in vitro passages of DEN\ or DENg.a
% increase in antigen-antibody binding^
in vitro passage
Tumor Line
Periodic
Acid
Treated
P50 P50
DENX 91.5 + 2.30 74.6 ±4.20 50.0 ± 3.50 45.3+4.60
PEN9 102.3 + 3.50 NP 30.3 + 3.50 10.2 ± 1.30
aIn vitro cultured, glutaraldehyde-fixed tumor cells were treated with 100
mM periodic acid (in PBS) and incubated at 37° C for 30 minutes.
Control wells received PBS. The binding of antibody (1:500 dilution of
sera of mice immunized with tissue culture cell lines) were measured
by ELISA.
% increase in the antibody binding was calculated by the
following formula:
% increase = P .P . (untreated) - P. P. (treated) X 100
P.P . (untreated)
''The values are the means of triplicate samples ± S.D.
ND = not done.
Periodic acid treatment did not change the binding of antibody to control
(MCS) cells.
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removal of the carbohydrate side chains from these
molecules appears to make the antigenic determinants
more accessible to the antibody and thus enhances
antigen-antibody binding capacity. The increased
expression of mucin-associated carbohydrate molecules
on the tumor cell surface was also shown to correlate with
aggressive tumor growth and poor prognosis of several
human cancers (Kobayashi et al. 1992, O'Boyle et al.
1992), suggesting that certain carbohydrate moieties on
the cell surface can protect the tumor cells from the host
immune destruction. The exposure of tumor cells to
neuraminidase, an enzyme that releases sialic acid from
cell surfaces, also enhanced antigen-antibody binding
(Table 6), further indicating that sialic acid-containing
carbohydrate chains can also mask the antigenic
determinants in this system. Similar observations have
been reported by other investigators (Bekesi et. al. 1972,
Ogasawara et al. 1988).
Although the treatment of the in vivo grown cells
with periodic acid or neuraminidase enhanced antigen-
antibody binding considerably, the highest percentage of
increase was obtained when early in vitro propagated
cells were used (Tables 6 and 7). It is possible that
concentrations of the interfering substances are much
greater on the surface of in vivo grown cells and longer
exposure time and higher concentrations of the enzymes
or periodic acid are required for their removal or
inactivation. However, the influence of other host factors
on the antigen-antibody binding cannot be excluded at
this time. It is also very likely that normal host cells,
that are inevitably mixed with in vivo tumor cell
suspensions, may have influenced the results and caused
the apparent reduction.
Interestingly, as in vitro cultivation continued, the
percentage of increase in antigen-antibody binding be-
tween the treated and untreated cells became smaller,
suggesting that during in vitro cultivation the masking
or interfering substances are gradually released from
the cell surface, and consequently the tumor cells be-
come more antigenic and bind the antibody more
efficiently. In contrast to in vitro experiments, the passages
of in vivo propagated cells serially into syngeneic mice
caused no detectable changes in antigen-antibody bind-
ing tests (data not shown), further confirming that during
in vivo cultivation antigenic determinants are not exposed
and are possibly masked by the interfering glycolipid or
glycoprotein molecules.
Although the mechanism(s) underlying the increase in
immunogenicity has not been well described, from the
data presented some credence might be given to each of
the following scenarios: 1) The majority of tumor cells
within a single tumor carry a tumor-associated antigen.
The antigen, however, may not be expressed on the cell
surface, or perhaps is modulated or masked by some host
factors (glycoproteins, glycolipids) which render them
non- or very weakly immunogenic. However, when these
cells are cultured in vitro, antigenic determinants are
gradually exposed and thus the cells become more
immunogenic. Immunization with immunogenic cultured
cells would then induce significant degrees of immunity
capable of acting on the in vivo propagated parental cell
line which, although unable to induce transplantation
immunity, is obviously immunosensitive. 2) All or the
majority of tumor cells within a single tumor possess
tumor-associated antigen, but the rapid rate of growth and
metastasizing capability of many malignant cells kill the
host or at least overcome any natural resistance before the
host can mount a specific immune response against
tumor-associated antigen(s) (Table 2). As a result of in
vitro cultivation, modification could occur in both the
rate of growth and ability of tumor cells to spread rapidly
in vivo (Table 3). Thus, the modified growth kinetics of
in vitro propagated tumor cells could allow the induction
of an effective immune response which would sub-
sequently inhibit the growth of more tumorigenic,
metastasizing in vivo tumor cells. 3) The tumor system
consists of heterogeneous cell subpopulations (Jamasbi
and Perkins 1990). As a result of in vitro selection,
subpopulations of cells with higher degrees of
immunogenicity become major components of the cell
culture. Thus the in vitro line would be more immuno-
genic than the in vivo counterpart. If the majority of tumor
cells carry different quantities or qualities of the same
antigen(s), then immunization with higher passaged
cultured cells could inhibit the growth of the less
immunogenic subpopulation which appears to have in
vivo growth advantages. None of these possibilities can
be excluded at this time, and it is reasonable to believe
that each one may play a role. The first possibility,
however, appears to correspond more closely with the
data presented here.
Periodic acid or neuraminidase treatment enhanced
antigen-antibody binding in vitro, indicating inhibitory
effects of glycoprotein and/or glycolipid molecules on the
antigen-antibody binding. The presence of tumor-
stimulating factors (Vaage 1978), suppressogenic
determinants (Klein et. al. 1981), antibody-mediated
epitope masking (Manson 1991) and shedding of the
antigen into circulation (Vinuela et al. 1991) which can
interfere with immune responses, has been described
by other investigators.
It has also been shown that the immunogenic potency
of poorly immunogenic tumor cells can be enhanced by
viral (Kobayashi et. al. 1969, Fearon et. al. 1988), chemical
(Bonmassar et. al. 1970, Ishikawa et. al 1987), and
mutagenic agents (Boon 1983). More recently, however,
procedures such as gene transductions have also been
applied for the same purpose (Mullen et al. 1992, Fearon
et al. 1988). The antigenic properties of these cell variants
may be explained by the concept of association-recognition
(Fearon et. al. 1988), which states that a single cell surface
antigenic determinant is insufficient to induce effective
host immune responses (Lake and Mitchison 1976, Boon
1983) and that the development of effective immune
responses require additional surface antigen or a helper
determinant to enable the host to respond to the newly
acquired antigen as well as to the tumor-associated
antigens (Kenne and Foreman 1982). Whether more than
one antigenic determinant would become exposed during
in vitro cultivation or whether association-recognition
plays any role in our study is not known and warrants
additional investigation.
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In summary, our observations demonstrated that:
1) different squamous cell carcinoma lines induced by
diethylnitrosamine (DEN) in the forestomach of BALB/c
mice show different degrees of tumorigenicity, metastatic
capability, and immunogenicity; 2) although some de-
gree of transplantation protection could be generated
against some of these tumor lines, this was not achieved
for others (e.g., the fast growing, highly malignant
tumors); 3) it was possible to induce a significant degree
of transplantation protection and circulating antibody
against these tumors when the animals were injected with
in vitro propagated cell line counterpart; and, 4) more
importantly, the antigen-antibody binding could be
enhanced substantially when the tumor cells were ex-
posed to periodic acid or neuraminidase prior to antigen-
antibody binding tests, suggesting that inaccessibility of
antigenic determinants on the surface of tumor cells in
vivo may be responsible for the difficulties associated
with the immunotherapy of certain cancers.
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